4.6 Review

Viral proteases as therapeutic targets

Journal

MOLECULAR ASPECTS OF MEDICINE
Volume 88, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.mam.2022.101159

Keywords

-

Funding

  1. National Institute of virology and bacteriology (Programme EXCELES) [LX22NPO5103]
  2. European Union-Next Generation EU

Ask authors/readers for more resources

Viral protease inhibitors are crucial in the treatment of chronic viral diseases, as they reduce drug resistance and potential side effects, and various protease inhibitors are routinely used in clinical practice.
Some medically important viruses-including retroviruses, flaviviruses, coronaviruses, and herpesviruses-code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid (R)), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available